FDA CBER Rejects Stephen J. Fallon's CAPA Response, Bars Future Clinical Trial Participation
FDA CBER rejects Dr. Fallon's CAPA response as insufficient, requiring a fully implemented plan before any future clinical trial participation.


CBER's follow-up letter to clinical investigator Stephen J. Fallon, Ph.D., makes the agency's enforcement posture explicit: acknowledging violations and self-declaring site incapacity is not a substitute for a documented, implemented CAPA plan that demonstrably prevents recurrence.
The November 13, 2026 letter, issued by the Division of Inspections and Surveillance under the Office of Compliance and Biologics Quality, closes the loop on Warning Letter CBER-26-728673 dated August 27, 2026. Fallon's September 2 response conceded the findings and stated that his site at 1401 NE 26th Street, Wilton Manors, FL, was not positioned to take on additional clinical trials. FDA found that concession insufficient. The corrective measures described were characterised as limited in scope and inadequate to address the identified violations on a sustained basis.
For QA directors overseeing clinical site networks, the enforcement language carries a direct operational read: admission of non-compliance does not satisfy the CAPA threshold under FDA's biologics framework. The agency requires a plan that has been implemented, not merely proposed, before any reinstatement of investigator qualification is considered. Fallon must now demonstrate qualified investigator status under applicable regulations before initiating any future investigation involving FDA-regulated products.
The letter also signals that CBER's monitoring posture remains active. Both Fallon individually and his study site remain under continued agency surveillance, meaning the compliance clock does not reset on submission of a revised CAPA alone. Regulatory affairs leads managing investigator qualification programmes should note that the bar for resolution in biologics enforcement is implementation evidence, not written intent.
The corrective action pathway available to Fallon requires submission of a comprehensive CAPA plan that has been implemented and adequately addresses each identified violation before any new clinical investigation may begin, a sequencing that places the burden of proof squarely on the investigator prior to agency review.
The outcome of Fallon's revised CAPA submission, and CBER's subsequent determination on investigator qualification, will serve as a measurable indicator of how the division applies its reinstatement standard in biologics clinical oversight.
Source: FDA Center for Biologics Evaluation and Research (CBER) via FDA.gov Warning Letters feed, November 20, 2026.

Reporting on the science, business and regulation shaping the pharmaceutical industry.
More from Pharma News
All stories →
India Positions Itself as Global Diabetes R&D Hub Targeting GLP-1 and Microbiome Therapies

Capricor Therapeutics Receives FDA Complete Response Letter for Deramiocel

Discussion